TCRT

Alaunos Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Houston, Texas, specializing in the development of groundbreaking immuno-oncology therapies aimed at treating cancer. The company leverages its proprietary T Cell Receptor (TCR) therapy platform to design more effective, targeted treatments for patients with solid tumors, representing a novel approach in the ongoing battle against cancer. With its advancements in clinical trials, Alaunos is well-positioned to significantly impact the oncology landscape, potentially delivering new treatment options that offer renewed hope for patients with historically challenging diagnoses.